XTSX
TELO
Market cap2mUSD
Jul 09, Last price
0.05CAD
1D
12.50%
1Q
-30.77%
Jan 2017
-99.01%
IPO
-97.63%
Name
Telo Genomics Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
24.00%
Rev. gr., 5y
%
Revenues
0k
Net income
-3m
L+0.21%
CFO
-2m
L-5.30%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Telo Genomics Corp. is a biotechnology enterprise focused on developing and commercializing sophisticated predictive technologies. Their mission is to enable personalized treatment approaches for patients facing specific health challenges. The company's central offering is a telomere analysis platform, which provides both diagnostic insights and prognostic assessments. This platform leverages liquid biopsies and related innovations, with a particular emphasis on applications within oncology (cancer) and neurological diseases. A flagship product, Telo-MM, is a solution designed to equip healthcare professionals with crucial, actionable information for managing Multiple Myeloma, a type of blood cancer. Additionally, the company provides TeloView, a proprietary software platform used to precisely measure specific telomere features unique to each patient. Telo Genomics serves a diverse client base, including pathologists, clinicians, academic researchers, and drug developers. They have a collaborative agreement with the Mayo Clinic to conduct validation studies for their Telo-MM tests concerning multiple myeloma. Founded in 2014, the company was initially known as 3D Signatures Inc. before officially changing its name to Telo Genomics Corp. in April 2019. Its headquarters are located in Toronto, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||